Compared to placebo what was the result of rivastigmine on AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale?
Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF.